What question did this study set out to answer?

To evaluate the prognostic value of standardized quantitative minimal residual disease assessment for relapse risk stratification in pediatric T-cell acute lymphoblastic leukemia.

July 1, 2011BloodOpen Access

Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study

View Full Paper

Ask AI

Bookmark

Authors

MSMartin Schrappe MVMaria Grazia Valsecchi CBClaus R. Bartram

Discussion

Member takes

Overview

Randomized trial demonstrates that day 78 minimal residual disease levels predict relapse in childhood T-cell leukemia, highlighting late clearance as a critical prognostic indicator.

Key Points

To evaluate the prognostic value of standardized quantitative minimal residual disease assessment for relapse risk stratification in pediatric T-cell acute lymphoblastic leukemia.
Stratified 464 children with T-cell acute lymphoblastic leukemia across protocols NCT00430118 and NCT00613457 using quantitative PCR targeting immunoglobulin and T-cell receptor gene rearrangements.
Categorized patients into standard risk (MRD negative at day 33 and day 78), intermediate risk (MRD positive at day 33 or 78 and < 10⁻³ at day 78), and high risk (MRD ≥ 10⁻³ at day 78).
Seven-year event-free survival was 91.1% (SE 3.5%) in standard-risk patients (16%), 80.6% (SE 2.3%) in intermediate-risk patients (63%), and 49.8% (SE 5.1%) in high-risk patients (21%) (P < .001).
MRD levels ≥ 10⁻³ at day 78 represented the strongest predictor of relapse, whereas achieving MRD negativity by day 78 yielded excellent survival (48% of all patients) regardless of day 33 positivity.

Cite This Study

Schrappe et al. (2011) studied this question.

synapsesocial.com/papers/6a105f85d13714ec96ffb391 https://doi.org/10.1182/blood-2011-03-338707

View Full Paper

Ask AI

Bookmark

July 1, 2011BloodOpen Access

Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study

View Full Paper

Ask AI

Bookmark

Authors

MSMartin Schrappe MVMaria Grazia Valsecchi CBClaus R. Bartram

Discussion

Member takes

Overview

Randomized trial demonstrates that day 78 minimal residual disease levels predict relapse in childhood T-cell leukemia, highlighting late clearance as a critical prognostic indicator.

Key Points

To evaluate the prognostic value of standardized quantitative minimal residual disease assessment for relapse risk stratification in pediatric T-cell acute lymphoblastic leukemia.
Stratified 464 children with T-cell acute lymphoblastic leukemia across protocols NCT00430118 and NCT00613457 using quantitative PCR targeting immunoglobulin and T-cell receptor gene rearrangements.
Categorized patients into standard risk (MRD negative at day 33 and day 78), intermediate risk (MRD positive at day 33 or 78 and < 10⁻³ at day 78), and high risk (MRD ≥ 10⁻³ at day 78).
Seven-year event-free survival was 91.1% (SE 3.5%) in standard-risk patients (16%), 80.6% (SE 2.3%) in intermediate-risk patients (63%), and 49.8% (SE 5.1%) in high-risk patients (21%) (P < .001).
MRD levels ≥ 10⁻³ at day 78 represented the strongest predictor of relapse, whereas achieving MRD negativity by day 78 yielded excellent survival (48% of all patients) regardless of day 33 positivity.

Cite This Study

Schrappe et al. (2011) studied this question.

synapsesocial.com/papers/6a105f85d13714ec96ffb391 https://doi.org/10.1182/blood-2011-03-338707

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark